In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor- 1
暂无分享,去创建一个
[1] B. Hinz,et al. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix , 2007, The Journal of cell biology.
[2] R. Cook,et al. Shear-induced Disulfide Bond Formation Regulates Adhesion Activity of von Willebrand Factor* , 2007, Journal of Biological Chemistry.
[3] Frauke Gräter,et al. Probing the chemistry of thioredoxin catalysis with force , 2007, Nature.
[4] Sabine Werner,et al. Keratinocyte-fibroblast interactions in wound healing. , 2007, The Journal of investigative dermatology.
[5] Zhiwei Yang,et al. Absence of integrin-mediated TGFβ1 activation in vivo recapitulates the phenotype of TGFβ1-null mice , 2007, The Journal of cell biology.
[6] D. Essex,et al. Redox modification of platelet glycoproteins. , 2006, Current drug targets.
[7] H. Versteeg,et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling , 2006, Proceedings of the National Academy of Sciences.
[8] K. Huber,et al. Predictive value of plasma plasminogen activator inhibitor‐1 for coronary restenosis: dependence on stent implantation and antithrombotic medication , 2005, Journal of thrombosis and haemostasis : JTH.
[9] B. Coller,et al. Antibody blockade or mutation of the fibrinogen gamma-chain C-terminus is more effective in inhibiting murine arterial thrombus formation than complete absence of fibrinogen. , 2004, Blood.
[10] S. Barry,et al. The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. , 2003, The Biochemical journal.
[11] E. Gilpin,et al. Impact of anesthesia on cardiac function during echocardiography in mice. , 2002, American journal of physiology. Heart and circulatory physiology.
[12] S. Gando. Disseminated Intravascular Coagulation in Trauma Patients , 2001, Seminars in thrombosis and hemostasis.
[13] N. Aikawa,et al. Elevation of plasma free PAI-1 levels as an integrated endothelial response to severe burns. , 2001, Burns : journal of the International Society for Burn Injuries.
[14] A. Ludlow,et al. Activation of Platelet-transforming Growth Factor β-1 in the Absence of Thrombospondin-1* , 2000, The Journal of Biological Chemistry.
[15] H. Lodish,et al. Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.
[16] E. Topol,et al. Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.
[17] S. Alper,et al. Hemodynamic shear stress and its role in atherosclerosis. , 1999, JAMA.
[18] B. Coller,et al. Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. , 1999, Biochemical and biophysical research communications.
[19] N. Kaminski,et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.
[20] M. Fishbein,et al. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. , 1998, Journal of the American College of Cardiology.
[21] R. Beyar,et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. , 1998, American heart journal.
[22] R. Busse,et al. Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. , 1997, Circulation.
[23] C. Bredahl,et al. Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. , 1995, Haemostasis.
[24] L. Wakefield,et al. Release and activation of platelet latent TGF–β in blood clots during dissolution with plasmin , 1995, Nature Medicine.
[25] D. Rifkin,et al. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. , 1994, Analytical biochemistry.
[26] M. Sporn,et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[27] G. Proetzel,et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.
[28] E. Holler,et al. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). , 1992, Thrombosis research.
[29] P. Browne,et al. Complexes of Thrombin with Proteins Secreted by Activated Platelets , 1992, Seminars in thrombosis and hemostasis.
[30] D. Loskutoff,et al. Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta. , 1991, Blood.
[31] Sporn,et al. Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. , 1988, The Journal of biological chemistry.
[32] K. Miyazono,et al. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. , 1988, The Journal of biological chemistry.
[33] M. Sporn,et al. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells , 1986, The Journal of cell biology.
[34] D. Lawrence,et al. Latent beta-transforming growth factor in nontransformed and Kirsten sarcoma virus-transformed normal rat kidney cells, clone 49F. , 1984, Cancer research.
[35] M. Sporn,et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. , 1983, The Journal of biological chemistry.
[36] A. Cumano,et al. Forced Unfolding of Proteins Within Cells , 2007 .
[37] F. Verrecchia,et al. Transforming growth factor-beta and fibrosis. , 2007, World journal of gastroenterology.
[38] J. Bluestone,et al. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. , 2007, Nature.
[39] H. von Melchner,et al. TGF-beta activation by traction? , 2004, Trends in cell biology.
[40] A. Ludlow,et al. Latent TGF-beta1 activation by platelets. , 2004, Journal of cellular physiology.
[41] D. Essex,et al. Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. , 2003, Blood.
[42] D. Rifkin,et al. Making sense of latent TGFbeta activation. , 2003, Journal of cell science.
[43] Jeffrey W. Smith,et al. Redox control of integrin adhesion receptors. , 2002, Methods in enzymology.
[44] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[45] D. Wilcken,et al. Circulating transforming growth factor beta 1 and coronary artery disease. , 1997, Cardiovascular research.
[46] J. Verheijen,et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. , 1985, Scandinavian journal of clinical and laboratory investigation.